Host distribution and response to antitumor alkylating agents of EMT-6 tumor cells from subcutaneous tumor implants

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 1, 1997, Pages 87-93

  Holden, Sylvia A ^a   Emi, Yasunori ^a   Kakeji, Yoshihiro ^a   Northey, David ^a   Teicher, Beverly A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Detection of micrometastases; Metastatic disease response; Tumor tissue distribution; Tumor host interaction

Indexed keywords

ALKYLATING AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; MELPHALAN; THIOTEPA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BONE MARROW; BRAIN; BREAST CARCINOMA; COLONY FORMATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER; LUNG; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TECHNIQUE; TISSUE DISTRIBUTION; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CISPLATIN; CYCLOHEXANES; CYCLOPHOSPHAMIDE; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MINOCYCLINE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASM, RESIDUAL; SESQUITERPENES; TISSUE DISTRIBUTION;

EID: 0030996246     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050631     Document Type: Article

References (37)

1. Antman K, Gale P (1988) High dose chemotherapy and autotransplants for breast cancer. Ann Intern Med 108:570
2. Astoul P, Colt HG, Wang X, Boutin C, Hoffman RM (1994) "Patient-like" nude mouse metastatic model of advanced human pleural cancer. J Cell Biochem 56:9
3. Corringhma R, Gilmore M, Prentice HG (1983) High-dose melphalan with autologous bone marrow transplant: treatment of poor prognosis tumors. Cancer 52:1783
4. Donelli MG, Russo R, Garattini S (1967) Selective chemotherapy in relation to the site of tumor transplantation, Int J Cancer 2:421
5. Dong Z, Radinsky R, Fan D, Tsan R, Bucana CD, Wilmanns C, Fidler IJ (1994) Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells. J Natl Cancer Inst 86:913
6. Fay JW, Levine MN, Phillips GL (1981) Treatment of metastatic melanoma with intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and autologous marrow transplantation (AMTX) (abstract). Proc Am Soc Clin Oncol 17:532
7. Frei E III (1985) Combined intensive alkylating agents with autologous bone marrow transplantation for melastatic solid tumors. In: Dicke K, Spitzer G, Zander A (eds) Autologous bone marrow transplantation: proceedings of the First International Symposium. The University of Texas M.D. Anderson Hospital and Tumor Institute at Houston, Houston, p 509
8. Frei E III (1985) Curative cancer chemotherapy. Cancer Res 45:6523
9. Frei III E, Canellos GP (1980) Dose: a critical factor in cancer chemotherapy. Am J Med 69:585
10. Frei E III, Antman K, Teicher B (1989) Bone marrow autotransplantation for solid tumors prospects. J Clin Oncol 7:515
11. Furukawa T, Kubota T, Watanabe M, Kuo T-H, Kitajima M, Hoffman RM (1993) Differential chemosensitivity of local and metastatic human gastric cancer after orthotopic transplantation of histologically intact tumor tisssue in nude mice. Int J Cancer 54:397
12. Glode LM (1979) Dose limiting extramedullary toxicity of high dose chemotherapy. Exp Hematol 7:265
13. Herzig G (1981) Autologous marrow transplantation in cancer therapy. Prog Hematol 12:1
14. Hill RP (1987) Excision assays. In: Kallman RF (ed) Rodent tumor models in experimental cancer therapy. Pergamon Press, New York, p 67
15. Kjonniksen I, Knut B, Fodstad O (1992) Site-dependent differences in sensitivity of LOX human melanoma tumors in nude rats to dacarbazine and mitozolomide, but not to doxorubicin and cisplatin. Cancer Res 52:1347
16. Knight III WA, Page CP, Kuhn JG (1984) High dose L-PAM and autologous marrow infusion for refractory solid tumors (abstract). Proc Am Soc Clin Oncol 3:150
17. Kubota T (1994) Metastatic models of human cancer xenografts in the nude mouse: the importance of orthotopic transplantation. J Cell Biochem 56:4
18. McElwain TJ, Hedley DW, Burton G (1979) Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. Br J Cancer 40:72
19. Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 23:571
20. Peters WP, Eder JP, Henner WD, Schryber S, Wilmore D, Finberg R, Schoenfeld D, Bast R, Gargone B, Antman K, Anderson J, Anderson K, Kriskall MS, Schnipper L, Frei E III (1986) High-dose combination alkylating agents with autologous bone marrow support: a phase I trial. J Clin Oncol 4:646
21. Phillips GL, Fay JW, Herzig GP, Herzig RH, Weiner RS, Wolff SN, Lazarus HM, Karanes C, Ross WE, Kramer BS (1983) Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. Cancer 10:1792
22. Poste G, Paruch L (1989) Stephen Paget, M.D., F.R.C.S., (1855-1926): a retrospective. Cancer Metastasis Rev 8:93
23. Santos G, Tutschka P, Brookmeyer R (1983) Marrow transplantation for acute non lymphocytic leukemia after treatment with busulfan and cyclophosphamide. New Engl J Med 309:1347
24. Slack NH, Bross ID (1975) The influence of site of metastasis on tumour growth and response to chemotherapy. Br J Cancer 32:78
25. Staroselsky AN, Fan D, O'Brian CA (1990) Site-dependent differences in response of the UV-2237 murine fibrosarcoma to systemic therapy with adriamycin. Cancer Res 50:7775
26. Teicher BA (1992) Preclinical models for high dose therapy. In: Armitage JO, Antman KH (eds) High-dose cancer therapy: pharmacology, hematopoietins, stem cells. Williams & Wilkins, Baltimore, p 14
27. Teicher BA (1995) Angiogenesis and cancer metastases: therapeutic approaches. In: Davis S (eds) Critical reviews in oncologoy/hematology. Elsevier Science Ireland, Amsterdam. p 9
28. Teicher BA (1995) Preclinical models for high-dose therapy. In: Armitage JO, Antman KH (eds) High-dose cancer therapy. Williams & Wilkins, Philadelphia, p 17
29. Teicher BA, Holden SA, Eder JP, Brann TW, Jones SM, Frei E III (1989) Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res 49:5994
30. Teicher BA, Holden SA, Jones SM, Eder JP, Herman TS (1989) Influence of scheduling on two-drug combinations of alkylating agents in vivo. Cancer Chemother Pharmacol 25:161
31. Teicher BA, Herman TS, Holden SA, Wang Y, Pfeffer MR, Crawford JM, Frei E III (1990) Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247:1457
32. Teicher BA, Holden SA, Ara G, Alvarez Sotomayor E, Huang ZD, Chen Y-N, Brem H (1994) Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents. Int J Cancer 57:920
33. Teicher BA, Dupuis N, Kusomoto T, Robinson MF, Liu F, Menon K, Coleman CN (1995) Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Invest 2:269
34. Teicher BA, Dupuis NP, Robinson M, Emi Y, Goff D (1995) Antiangiogenic treatment (TNP-470 minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncology Res 7:237
35. Thomas ED (1982) The role of marrow transplantation in the eradication of malignant disease. Cancer 49:1963
36. Wilmanns C, Fan D, O'Brian CA (1992) Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer 52:98
37. Wilmanns C, Fan D, O'Brian CA, Radinsky R, Bucana CD, Tsan R, Fidler IJ (1993) Modulation of doxorubicin sensitivity and level of p-glycoprotein expression in human colon carcinoma cells by ectopic and orthotopic environments in nude mice. Int J Oncol 3:413